SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-026904
Filing Date
2022-10-24
Accepted
2022-10-24 17:20:17
Documents
12
Period of Report
2022-10-24
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20221024.htm   iXBRL 8-K 41450
  Complete submission text file 0001628280-22-026904.txt   183487

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20221024.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20221024_lab.xml EX-101.LAB 24927
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20221024_pre.xml EX-101.PRE 13133
6 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20221024_htm.xml XML 11578
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 221326590
SIC: 2834 Pharmaceutical Preparations